Central Banks' 'Higher for Longer' Rates: As a clinical-stage biotechnology company, Assembly Biosciences relies heavily on capital to fund its research and development. Elevated interest rates increase the cost of borrowing and can make it more challenging to secure funding or attract investors for speculative, long-term growth assets, directly impacting the company's financial runway and valuation of future cash flows.

Q1 2026 Earnings Season: The overall sentiment and results from other biotechnology and pharmaceutical companies during earnings season can significantly influence investor perception of the sector. Positive or negative surprises from peers could create ripple effects, impacting ASMB's stock performance regardless of its specific financial situation, particularly given its clinical-stage nature.

General Market Risk Aversion due to Geopolitical Events (Iran War Escalation, Strait of Hormuz Closure): Increased global instability often prompts investors to move away from higher-risk assets like small-cap biotechnology stocks, leading to a 'flight to safety'. This can result in broader market downturns or increased volatility, negatively affecting ASMB's share price irrespective of company-specific developments.